7.77
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Low
0.6018
High
10.15
Best deals to access real time data! |
Big Cap Pro
Monthly Subscription
for only
|
Small Cap Pro
Monthly Subscription
for only
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
VAT not included
|
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Scynexis Inc | SCYX | NASDAQ | Common Stock |
Price Change | Change Percent | Stock Price | Last Traded ![]() |
|
---|---|---|---|---|
0.00 | 0.0% | 7.77 | 04:00:00 |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
7.77 |
Bid Price | Ask Price | Spread | News | |
---|---|---|---|---|
4.38 | 8.50 | 4.12 | - | - |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 7.77 | USD |
Scynexis Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 149.81M | 19.28M | 17.32M | $ 121.00k | $ - | -9.79 | -2.10 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | 0.00% | - | - |
Scynexis News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SCYX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 8.40 | 8.70 | 7.65 | 8.00 | 234,390 | -0.63 | -7.5% |
1 Month | 8.25 | 8.76 | 7.01 | 8.10 | 309,331 | -0.48 | -5.82% |
3 Months | 8.86 | 10.15 | 6.75 | 8.30 | 662,371 | -1.09 | -12.3% |
6 Months | 5.25 | 10.15 | 4.25 | 7.88 | 449,541 | 2.52 | 48.0% |
1 Year | 0.99 | 10.15 | 0.6018 | 3.86 | 543,257 | 6.78 | 684.85% |
3 Years | 1.28 | 10.15 | 0.35 | 1.97 | 618,932 | 6.49 | 507.03% |
5 Years | 4.1716 | 10.15 | 0.35 | 2.17 | 524,132 | 3.60 | 86.26% |
Scynexis Description
SCYNEXIS Inc is drug development company which focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing lead product candidate, SCY-078 which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The SCY-078 is a novel and structurally distinct triterpenoid glucan synthase inhibitor which is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains. |